Hortobagyi GN - Search Results

1

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, Xiong Y, Zhang S, Krop IE, Winer EP, Kindelberger DW, Coviello J, Sahin AA, Nuñez R, Hortobagyi GN, Yu D, Esteva FJ. Morrow PK, et al. Among authors: hortobagyi gn. J Clin Oncol. 2011 Aug 10;29(23):3126-32. doi: 10.1200/JCO.2010.32.2321. Epub 2011 Jul 5. J Clin Oncol. 2011. PMID: 21730275 Free PMC article. Clinical Trial.

2

Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer.

Walters RS, Theriault RL, Holmes FA, Hortobagyi GN, Esparza L. Walters RS, et al. Among authors: hortobagyi gn. Invest New Drugs. 1992 Apr;10(1):43-4. doi: 10.1007/BF01275480. Invest New Drugs. 1992. PMID: 1376723 Clinical Trial.

3

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.

Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al. Buzdar AU, et al. Among authors: hortobagyi gn. J Clin Oncol. 1992 Oct;10(10):1540-6. doi: 10.1200/JCO.1992.10.10.1540. J Clin Oncol. 1992. PMID: 1403033 Clinical Trial.

4

Activity of ifosfamide in breast cancer.

Hortobagyi GN. Hortobagyi GN. Semin Oncol. 1992 Dec;19(6 Suppl 12):36-41. Semin Oncol. 1992. PMID: 1485173 Review.

5

Treatment of locally advanced breast cancer.

Booser DJ, Hortobagyi GN. Booser DJ, et al. Among authors: hortobagyi gn. Semin Oncol. 1992 Jun;19(3):278-85. Semin Oncol. 1992. PMID: 1609294 Review.

6

Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis.

Sahin AA, Ro J, Ro JY, Blick MB, el-Naggar AK, Ordonez NG, Fritsche HA, Smith TL, Hortobagyi GN, Ayala AG. Sahin AA, et al. Among authors: hortobagyi gn. Cancer. 1991 Aug 1;68(3):549-57. doi: 10.1002/1097-0142(19910801)68:3<549::aid-cncr2820680318>3.0.co;2-j. Cancer. 1991. PMID: 1648433

7

Lack of correlation between histologic findings and response to chemotherapy in metastatic breast cancer.

Ziegler LD, Connelly JH, Frye D, Smith TL, Hortobagyi GN. Ziegler LD, et al. Among authors: hortobagyi gn. Cancer. 1991 Aug 1;68(3):628-33. doi: 10.1002/1097-0142(19910801)68:3<628::aid-cncr2820680331>3.0.co;2-3. Cancer. 1991. PMID: 1648436

8

Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy.

Buzdar AU, Kau SW, Hortobagyi GN, Ames FC, Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Buzdar AU, et al. Among authors: hortobagyi gn. Cancer. 1992 Jan 15;69(2):448-52. doi: 10.1002/1097-0142(19920115)69:2<448::aid-cncr2820690229>3.0.co;2-k. Cancer. 1992. PMID: 1728373

9

Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer.

Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA. Macheledt JE, et al. Among authors: hortobagyi gn. Breast Cancer Res Treat. 1991 Aug;18(3):165-70. doi: 10.1007/BF01990032. Breast Cancer Res Treat. 1991. PMID: 1756259 Clinical Trial.

10

Phase I-II study of high-dose etoposide in patients with refractory breast cancer.

Fraschini G, Holmes FA, Esparza L, Theriault RL, Buzdar AU, Hortobagyi GN. Fraschini G, et al. Among authors: hortobagyi gn. Invest New Drugs. 1991 Nov;9(4):365-7. doi: 10.1007/BF00183583. Invest New Drugs. 1991. PMID: 1804815 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,106 results

Search Page

Filters